RxDoctor Payments Data

Neil Trask, MD

Cardiovascular Disease · Myrtle Beach, SCNPI 1861488710

Payments from drug & device makers

$813in general payments, 2019–2025

Across 50 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$121
  • Novo Nordisk$119
  • Johnson & Johnson$115
  • Kowa Pharmaceuticals America, Inc.$62
  • Amgen$59
  • Boston Scientific$50
  • plus $289 from 10 others

What the payments were for

  • Food & beverage$80098%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$813 in reported general payments places this provider in the 20th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$414,829
Medicare patients
1,127
Services billed
8,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban463$535,688
EntrestoSacubitril/Valsartan159$204,480
XareltoRivaroxaban148$192,425
MultaqDronedarone Hcl19$28,013
JardianceEmpagliflozin32$21,775
WegovySemaglutide14$18,550
Repatha SureclickEvolocumab23$16,583
Dofetilide52$9,565
Metoprolol Succinate401$7,715
Flecainide Acetate86$6,897
Ezetimibe129$5,668
Atorvastatin Calcium411$5,000
Rosuvastatin Calcium372$4,876
Dabigatran EtexilateDabigatran Etexilate Mesylate12$4,757
Losartan Potassium298$4,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$204,480159 claims
Johnson & JohnsonXarelto$115$192,425148 claims
Boehringer IngelheimJardiance$23$21,77532 claims
Novo NordiskWegovy$119$18,55014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →